Nephrocare India, has secured Rs 8.08 crore in its pre-IPO round to bridge the growing need for renal care in India, the company revealed on Friday.
The fresh investment will help accomplish Nephrocare India’s target of setting up 22 high-end kidney care facilities across India by March 2026. Four centres are expected to be operational by the end of the current fiscal, the company said in a statement.
The Kolkata-based comprehensive renal care provider, has now set a target to open 300 Nephrocare clinics across the country over the next 8-10 years. Explaining the significance for such an expansion drive, company officials stated, the vast demand for kidney care units in India.
Nephrocare India secures ₹8.08 Crore in fresh round of funding
With an estimated seven crore patients grapling with chronic kidney diseases and only around 12,881 haemodialysis centres nationwide, access to proper treatment remains severely restricted.
Nearly one in eleven Indians are prone to renal failure which is often driven by diabetes and hypertension, the officials quoted. India, dubbed the ‘diabetes capital of the world’, adds approximately 2.5 lakh new dialysis-dependent patients annually due to advanced kidney conditions, Nephrocare India representatives mentioned.
The funding round by Nephrocare India saw participation from marquee investors, who include former HDFC Ltdchairman Deepak Parekh, HDFC Securities chairman Bharat Shah, and founder and MD of Macleods Pharmaceuticals Rajendra Agarwal.
